Astellas Pharma Inc. (TYO:4503)
Japan flag Japan · Delayed Price · Currency is JPY
2,471.50
-201.00 (-7.52%)
Nov 6, 2026, 3:30 PM JST

Astellas Pharma Balance Sheet

Millions JPY. Fiscal year is Apr - Mar.

Assets

Fiscal Year
TTMFY 2026FY 2025FY 2024FY 2023FY 2022
Period Ending
Sep '26 Mar '26 Mar '25 Mar '24 Mar '23 Mar '22
Cash & Equivalents
238,228281,605188,372335,687376,840315,986
Cash & Short-Term Investments
238,228281,605188,372335,687376,840315,986
Cash Growth
-17.01%49.49%-43.89%-10.92%19.26%-3.11%
Accounts Receivable
813,461746,808632,525534,985427,965382,462
Other Receivables
12,31714,95513,69113,05117,81321,539
Receivables
825,778761,763646,216548,036445,778404,001
Inventory
324,020331,014297,261248,738174,386153,072
Other Current Assets
56,34947,54169,50062,26952,95050,295
Total Current Assets
1,444,3751,421,9231,201,3491,194,7301,049,954923,354
Property, Plant & Equipment
358,197358,424328,921293,742286,459269,044
Long-Term Investments
19,443202,001172,239163,018145,028141,206
Goodwill
437,978441,175415,207418,694328,411303,030
Other Intangible Assets
934,159996,9321,123,7141,453,824562,496623,431
Long-Term Deferred Tax Assets
137,794146,58898,11345,59484,16972,331
Other Long-Term Assets
195,836-1111-1
Total Assets
3,527,7823,567,0423,339,5443,569,6032,456,5182,332,395

Liabilities

Fiscal Year
TTMFY 2026FY 2025FY 2024FY 2023FY 2022
Period Ending
Sep '26 Mar '26 Mar '25 Mar '24 Mar '23 Mar '22
Accounts Payable
187,584199,752187,840185,193140,236130,739
Accrued Expenses
-193,886169,119155,233143,817136,553
Short-Term Debt
74,900-184,874420,39375,00090,000
Current Portion of Long-Term Debt
80,021245,95281,65851,885-50,000
Current Portion of Leases
-17,61516,33514,94413,54617,730
Current Income Taxes Payable
49,25868,93434,54938,5155,13732,388
Other Current Liabilities
708,034492,262387,235419,562348,298230,001
Total Current Liabilities
1,099,7971,218,4011,061,6101,285,725726,034687,411
Long-Term Debt
270,000320,000564,893449,93754,217676
Long-Term Leases
-88,78689,32670,75661,46155,014
Pension & Post-Retirement Benefits
21,55721,47322,74624,67424,81837,226
Long-Term Deferred Tax Liabilities
4,2341,2755,35351,3466,0485,823
Other Long-Term Liabilities
148,78486,22382,36191,17775,98685,937
Total Liabilities
1,544,3721,736,1581,826,2891,973,615948,564872,087

Shareholders' Equity

Fiscal Year
TTMFY 2026FY 2025FY 2024FY 2023FY 2022
Period Ending
Sep '26 Mar '26 Mar '25 Mar '24 Mar '23 Mar '22
Common Stock
103,001103,001103,001103,001103,001103,001
Additional Paid-In Capital
182,110185,162185,259184,070181,280179,467
Retained Earnings
1,082,101902,836740,939809,400908,158944,261
Treasury Stock
-31,390-34,945-37,524-33,783-25,123-13,934
Comprehensive Income & Other
645,891672,990521,580533,300340,638247,513
Total Common Equity
1,981,7131,829,0441,513,2551,595,9881,507,9541,460,308
Minority Interest
1,6971,840----
Shareholders' Equity
1,983,4101,830,8841,513,2551,595,9881,507,9541,460,308
Total Liabilities & Equity
3,527,7823,567,0423,339,5443,569,6032,456,5182,332,395

Additional Metrics

Fiscal Year
TTMFY 2026FY 2025FY 2024FY 2023FY 2022
Period Ending
Sep '26 Mar '26 Mar '25 Mar '24 Mar '23 Mar '22
Total Debt
424,921672,353937,0861,007,915204,224213,420
Net Cash (Debt)
-186,693-390,748-748,714-672,228172,616102,566
Net Cash Growth
----68.30%116.09%
Net Cash Per Share
-103.87-217.43-416.61-373.5394.5855.42
Filing Date Shares Outstanding
1,7931,7911,7901,7931,7971,827
Total Common Shares Outstanding
1,7931,7911,7901,7931,7971,827
Working Capital
344,578203,522139,739-90,995323,920235,943
Book Value Per Share
1105.171020.96845.25890.07839.26799.26
Tangible Book Value
609,576390,937-25,666-276,530617,047533,847
Tangible Book Value Per Share
339.95218.22-14.34-154.22343.42292.19